Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 3,333.9% in October

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 374,300 shares, an increase of 3,333.9% from the September 30th total of 10,900 shares. Based on an average daily volume of 715,100 shares, the days-to-cover ratio is presently 0.5 days.

Chugai Pharmaceutical Trading Up 3.4 %

Shares of Chugai Pharmaceutical stock opened at $23.60 on Friday. The company’s fifty day simple moving average is $23.90 and its two-hundred day simple moving average is $19.71. The company has a market cap of $77.64 billion, a P/E ratio of 34.71 and a beta of 0.89. Chugai Pharmaceutical has a 12-month low of $14.10 and a 12-month high of $26.00.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.03 billion for the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. Analysts predict that Chugai Pharmaceutical will post 0.78 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.